Which antispasmodic medication is safe to use during pregnancy?

Which Antispasmodic is Safe in Pregnancy

Based on the most recent and highest quality guideline evidence, hyoscine butyl-bromide (Spasfon) and drotaverine hydrochloride are the safest antispasmodics for use during pregnancy, with the strongest safety data supporting their use during labor.

Evidence-Based Recommendations

First-Line Antispasmodics in Pregnancy

The 2024 BJOG guideline on nausea and vomiting in pregnancy 1 and the 2012 gastroenterology sedation curriculum 2 both emphasize using Category A or B drugs during pregnancy whenever possible. For antispasmodics specifically used during labor:

• Hyoscine butyl-bromide (Spasfon): Research demonstrates excellent safety profile with no serious maternal or neonatal adverse events 3, 4. A 2004 study showed 95.6% effectiveness in reducing cervical edema with no significant side effects, compared to atropine which caused thirst and tachycardia in multiple patients 3.

• Drotaverine hydrochloride: Included in the Cochrane systematic review of antispasmodics for labor 4, showing reduction in first stage of labor duration by approximately 66 minutes with no serious adverse events reported.

• Rociverine: A 2011 randomized controlled trial demonstrated safety during labor with faster cervical dilatation (2.43 vs 1.85 cm/hour) and no recorded adverse effects 5.

Key Safety Considerations

Avoid these antispasmodics during pregnancy:

• The 2012 guideline 2 emphasizes avoiding Category D and X drugs
• The 2022 diabetes in pregnancy guideline 6 specifically contraindicates ACE inhibitors and angiotensin receptor blockers
• Any antispasmodic with anticholinergic properties that cause significant maternal tachycardia (like atropine) should be used cautiously 3

Practical Application Algorithm

For gastrointestinal spasm in pregnancy:

1. Use hyoscine butyl-bromide as first-line (best safety data)
2. Consider drotaverine as alternative
3. Avoid medications with strong anticholinergic effects that cause maternal tachycardia

For labor management:

1. Hyoscine butyl-bromide 80mg IV or drotaverine can reduce first stage duration by 60-90 minutes 4
2. Administer when cervix is 2-3 cm dilated for optimal effect 3
3. Monitor for maternal tachycardia (main adverse effect, though rare with hyoscine)

Important Caveats

The 2012 guideline 2 recommends using the lowest effective dose of any medication during pregnancy and delaying procedures until the second trimester when possible. The Cochrane review 4 notes that while antispasmodics reduce labor duration, the overall quality of evidence is low to moderate, and maternal/neonatal adverse events were reported inconsistently across studies.

Critical timing consideration: The 2022 diabetes guideline 6 and 2015 cardiac arrhythmia guideline 7 both emphasize that first trimester exposure carries the highest risk of congenital malformations, so antispasmodics should ideally be avoided during weeks 1-12 unless absolutely necessary.

Monitoring Requirements

When antispasmodics are used during pregnancy 2:

• Confirm fetal heart sounds before and after administration
• Position patient in left lateral position to avoid vena caval compression
• Have obstetric support available
• Monitor maternal heart rate (primary adverse effect is tachycardia)

The evidence consistently supports hyoscine butyl-bromide and drotaverine as the safest options, with the most robust data coming from labor studies showing both efficacy and safety for mother and neonate 5, 3, 4.